Intracerebroventricular administration of gm1 ganglioside to presenile alzheimer patients

Dementia and Geriatric Cognitive Disorders

Volumn 8, Issue 1, 1997, Pages 26-33

  Augustinsson, L E ^a   Blennow, K ^a   Blomstrand, C ^a   Brane G ^a   Ekman, R ^a   Fredman, P ^a   Karlsson, I ^a   Kihlgren, M ^b   Lehmann, W ^a   Lekman, A ^a   Mansson J E ^a   Ramstrom I ^a   Wallin, A ^a   Wikkelso C ^a   Gottfries, C G ^a   Svennerholm, L ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

Alzheimer s disease; GMI1 ganglioside; Gottfries Br and aring; ne Steen rating scale; Intracerebroventricular; Regional cerebral blood flow; Training program; Transmitter substances

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; GANGLIOSIDE GM1; HOMOVANILLIC ACID; SOMATOSTATIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; PRESENILE DEMENTIA; PRIORITY JOURNAL; STEREOTAXIS;

EID: 0030942346     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106597     Document Type: Article

References (36)

1. Svennerholm L: The gangliosides. J Lipid Res 1964;5:145-155.
2. Svennerholm L: Chromatographic separation of human brain gangliosides. J Neurochem 1963;10:613-623.
3. Agnati LF, Fuxe K, Calza L, Benfenati F, Ca-vicchioli L, Toffano G. Goldstein M: Gangliosides increase the survival of lesioned nigral dopamine neurons and favour the recovery of dopaminergic synaptic function in striatum of rats by collateral sprouting. Acta Phvsiol Scand 1983;1 19:347-363.
4. Sabcl BA, Slavin MD, Stein DG: GM1 ganglio-sidc treatment facilitates behavioural recovery from bilateral brain damage. Science 1984;225: 340-342.
5. Sofronicw MV. Pearson RCA. Cuello AC, Ta-gari PC, Stephens PH: Parentcrally administered GM1 ganglioside prevents retrograde degeneration of cholinergic cells of the rat basal forebrain. Brain Res 1986;398:393-396.
6. Sabcl BA, Dclmastro R, Dunbar GL, Stein DG: Reduction of anterograde degeneration in brain damaged rats by GM1-gangliosides. Ncu-rosciLett 1987;77:360-366.
7. Hansson H-A, Holmgren J, Svennerholm L: Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. Proc Natl AcadSci USA 1977;74:3782-3786.
8. Miceli G, Caltagirone C, Gainotti G: Gangliosides in the treatment of mental deterioration. Acta Psychiatr Scand 1977;55:102-110.
9. Cuello AC: Glycosphingolipids that can regulate nerve growlh and repair. Adv Pharmacol 1990;21:1-50.
10. Snider WD, Johnson EM. Neurotrophic molecules. Ann Neurol 1989:26:489-506.
11. Hcrrero MT, Perez-Otano I, Oset C, Kastner A, Hirsch EC, Agid J, Luquin MR, Obeso JA, Del Rio J: GM 1-gangliosidc promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Neuroscience 1993;56:965-972.
12. Suzuki K, Katzman R, Korey SR: Chemical studies on Alzhcimer’s's disease. J Neuropa-thol Exp Neurol 1965;24:211-224.
13. Svennerholm L, Gottfries C-G: Membrane lipids, selectively diminished in Alzheimer’s brains suggest synapse loss as a primary event in carly-onset form (type I) and demyelination in latc-onsct form (type II). J Neurochem 1994; 62:1039-1047.
14. Svennerholm L. Gottfries C-G. Blcnnow K, Fredman P. Karlsson I. Mansson J-E, Toffano G, Wallin A: Parenteral administration of GM1 ganglioside to presenili Alzheimer's patients. Acta Neurol Scand 1990:81:45-53.
15. Ala T. Romero S. Knight F. Feldt K. Frey WH: GM 1-treatment of Alzheimer’s's disease: A pilot study of safety and efficacy. Arch Neurol 1990;47:1126-1130.
16. Flicker C, Ferris SH, Kalkstcin D, Scrby M: A double-blind, placebo controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease. Am J Psychiatry 1994,151: 126-129.
17. Wallin A, Blennotv K, Schctens P: Research criteria for the clinical diagnosis of pure Alzheimer’s disease. Drugs Today 1994;4:265-273.
18. McKhann G, Drachman D. Folstein M. Katzman R, Price D. Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS ADRDA work group under the auspices ofDepartmcnt ofHealth and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
19. Gottfries C-G. Brine G. Gullberg B. Steen G: A new rating scale for dementia syndromes. Arch Gerontol Gcriatr 1982; 1:311-330.
20. DiMartino A. Safar J. Ceroni M. Gibbs CJ. Jr.: Purification of non infectious ganglioside preparations from scrapie-infected brain tissue. Arch Virol 1992;124:111-121.
21. Folstein M, Folstein S, McHugh PR: Minimental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
22. Fuld P: Guaranteed stimulus-processing in the evaluation of memorv and learning. Cortex 1980;16:255-272.
23. Wechsler D: Manual for the Wcchsler Adult Intelligence Scale. New York. Psychological Corporation, 1955.
24. Lczak MD: Neuropsychological Assessment. New York, Oxford University Press, 1983.
25. Rosen WG, Moks RC, Davis KL: A new’ rating scale for Alzheimer’s disease. Am J Psych 1984;141:1356-1364.
26. Larsson A, Bergh A-C, Billing M, Arlig A, Jacobsson L, Stephenscn H, Wikkelso C: Regional cerebral blood low in normal pressure hydrocephalus: Diagnostic and prognostic aspects. Eur J Nucl Med 1994:21:118-123.
27. m-HMPAO SPECT. Nucl Med Commun 1994: 15:814-823.
28. Blennotv K, Fredman P, Wallin A, Gottfries CG, Skoog I, Svennerholm L, Wikkelso C: Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age. Eur Neurol 1993:33:129-133.
29. Blennotv K. Rybo E. Wallin A. Gottfries CG. Svennerholm L; Cerebrospinal fluid cytology in Alzheimer’s disease. Dementia 1991:2:25-29.
30. Lckman A. Witt-Engerstrdm I, Holmbcrg B, Percy A, Hagberg B, Svennerholm L: CSF and urine biogenic amine metabolites in Rett syndrome. Clin Genet 1990:37:173-178.
31. Edvinsson L. Minthon L. Ekman R. Gustafson L: Neuropeptides in cerebrospinal fluid of patients with Alzheimer’s disease and dementia with frontotemporal lobe degeneration. Dementia 1993:4:167-171.
32. Fredman P, Lycke J, Andersen O, Vrethcrn M, Emcrudh J, Svennerholm L: Peripheral neuropathy associated with monoclonal IgM antibody toglvcolipids with a terminal glucuronyl-3-suIfate epitope. J Neurol 1993:240:381-387.
33. Svennerholm L: Gangliosides: A new therapeutic agent against stroke and Alzheimer’s disease. LifeSci 1994:55:2125-2134.
34. Schneider JS. Roetgen DP. Rothblat DS. et al: GM1 ganglioside treatment of Parkinson's disease: An open study of safety and efficacy. Neurology 1995:45:1149-1154.
35. Hillier-Park S. Pilisuk M: Caregiver burden: Gender and the psychological costs of care giving. Am J Orthopsychiatry 1990:61:501-509.
36. Nyth AL: Alzheimer’s Disease: Aspects on Treatment and Course; thesis University of Gotcborg, 1992.